Hormone therapyFDA-approvedSecond-line
Zytiga
Generic name: abiraterone
How it works
Blocks the production of testosterone, a hormone that fuels prostate cancer growth.
Cancer types
Prostate Cancer— All patients
Efficacy
Studies show that abiraterone can slow cancer growth and reduce symptoms in around 80% of patients.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| Evaluating a New Medicine for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Low-Dose Abiraterone May Be a Feasible Alternative for Prostate Cancer Treatment | Prostate Cancer | phase-3 | Median PSA-PFS was 5.7 months with low-dose versus 3.8 months with standard-dose AA. | Source → |
| New Treatment Combination Shows Promise for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 38.6 months in the niraparib + AAP group versus 8.3 months in the placebo + AAP group. | Source → |
| Testing Xaluritamig Plus Abiraterone for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone Acetate May Help Fight Prostate Cancer by Triggering Stress Response | Prostate Cancer | lab-study | AA induced concentration/time-dependent cytotoxicity in LNCaP cells (24 h IC₅₀ = 4.8 μM) and 22Rv1 cells (24 h IC₅₀ = 15.2 μM) and proliferation decreased by 54.1% and 7.3% at 4.8 μM, respectively. | Source → |
| Genetic Link to Abiraterone Dosage Identified in Prostate Cancer Study | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Enzalutamide Show Similar Outcomes in Prostate Cancer | Prostate Cancer | observational | Median overall survival was 36.2 months for both abiraterone and enzalutamide. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Combining Trastuzumab Deruxtecan and Abiraterone Shows Promise in Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Enzalutamide May Offer Better Survival for Prostate Cancer Patients | Prostate Cancer | observational | Enzalutamide-treated patients had longer overall survival in the first-line setting (HR: 0.84) and the second-line setting (HR: 0.88). | Source → |
| New Delivery System for Prostate Cancer Treatment Shows Promise | Prostate Cancer | lab-study | The dissolution study demonstrated significantly higher ABT release from ABT-ssSNEDDS in comparison to free ABT after 2 h in pH 1.2 and 6.8 pH buffer. | Source → |
| Comorbidities Affect Abiraterone Treatment in Prostate Cancer | Prostate Cancer | meta-analysis | — | Source → |
| Modified Monitoring of Abiraterone May Reduce Liver Damage in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Comparing Prostate Cancer Treatments: Abiraterone, Enzalutamide, and Apalutamide | Prostate Cancer | observational | Abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). | Source → |
| Abiraterone Resistance in Prostate Cancer Linked to CENPK Splice Variant | Prostate Cancer | lab-study | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| Abiraterone Treatment in Prostate Cancer: Early Response Matters | Prostate Cancer | phase-2 | Those patients with hetero-responding disease had significantly different PFS compared to the responding and non-responding groups (hazard ratio: responding group = reference, hetero-responding group = 4.0, non-responding group = 5.8; p < 0.0001). | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | Patients initiating enzalutamide had a 0.90-month longer overall survival compared to those initiating abiraterone acetate at 4 years. | Source → |
| Long-term effects of prostate cancer treatment studied | Prostate Cancer | phase-2 | A significant association between higher abiraterone acetate concentrations and better clinical benefit was observed (p = 0.041). | Source → |
| Abiraterone Efficacy Predicted by Prostate Cancer Biomarker | Prostate Cancer | observational | The median PSA-PFS was 11.43 months versus 26.43 months in patients with KI67 ≥ 30% versus those with KI67 < 30%. | Source → |
| Abiraterone May Cause Heart Rhythm Problem in Some Patients | Prostate Cancer | observational | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| New Study Compares Effectiveness of Two Cancer Drugs for Prostate Cancer | Prostate Cancer | phase-3 | The median PSA response rate was -65.4% with abiraterone and -78.8% with enzalutamide. | Source → |
| Genetic variant linked to poorer prostate cancer treatment outcomes | Prostate Cancer | observational | A total of 54 patients (20%) had the variant, which was associated with a significantly worse overall survival (HR = 1.71, 95% CI 1.09 - 2.68, p = 0.019) and time to progression (HR = 1.50, 95% CI 1.08 - 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 - 0.96, p = 0.038). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.